TM6SF2 and metabolic dysfunction-associated steatotic liver disease: The aim of the current study was, first, to determine whether the association with NAFLD reported by Kozlitina et al.19 could be independently validated; and, second, to establish whether the TM6SF2 rs58542926 variant was associated with clinically important disease end points that have prognostic relevance (in particular stage of hepatic fibrosis or development of NAFLD-related HCC).